Discontinuation and nonpublication of interventional clinical trials conducted in patients with mild cognitive impairment and Alzheimer's disease

Abstract

IntroductionDiscontinuation and nonpublication of interventional clinical trials represents a waste of already scarce resources. We sought to identify the prevalence of discontinuation and nonpublication of interventional clinical trials conducted in patients afflicted by mild cognitive impairment and Alzheimer's disease.MethodsWe conducted a retrospective, cross-sectional study on mild cognitive impairment and Alzheimer's disease–based interventional clinical trials in ClinicalTrials.gov dating back to 1995. The analyzed data included trial phase, intervention type, enrollment, and funding sources. Fisher's exact and χ2 tests were used to determine any potential associations between trial characteristics and completion.ResultsA total of 744 studies were identified, of which 502 (67%) were industry-sponsored ones. A total of 127 (17%) were discontinued prematurely. Of the 617 completed trials, 450 (73%) were not published, representing approximately 66,655 participants who incurred the risks of trial participation without subsequently contributing to the medical literature. Similarly, there were 18,246 patients from unpublished, discontinued trials. Of the 744 trials examined, 247 publications from 167 trials could be identified via PubMed/MEDLINE and EMBASE searches. Most notably, the odds of nonpublication among industry-sponsored trials were more than 75% higher than those in studies funded by academia (odds ratio = 1.78; 95% confidence interval, 1.14–2.78; P = .01). Furthermore, industry-sponsored trials had a 50% greater odds of study discontinuation compared with trials funded by academia (odds ratio = 1.50; 95% confidence interval, 1.04–2.16; P = .03).DiscussionThe nonpublication of many trials and preliminary results of trials that are discontinued early dilutes the quality and decreases the comprehensive nature of the medical literature. This occurs in both industry and academia. Publication of inconclusive or negative results ensures that all research activities, regardless of outcome, contribute to global medical knowledge.

Premature termination of interventional ophthalmology clinical trials from international registries

“…However, further action is needed to ensure that findings of all trials are shared with the medical community in order to build a more comprehensive body of knowledge and decrease potential redundancy. 7 Publication of inconclusive or negative results ensures that all research activities, regardless of outcome, contribute to global medical knowledge and the advancement of the field.…”

The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases

“…CTs at different phases; 80% involved drug investigations. 277 Despite extensive efforts and enormous investment, only two classes of drugs, presenting mild symptomatic effects, have been introduced in clinical practice nearly two decades ago: cholinesterase blockers (rivastigmine, donepezil, galantamine) and one antagonist of glutamate NMDA receptors (i.e., memantine). A drug capable of modifying the natural trajectory of AD, thereby reducing its progression, is still lacking.…”

“…One identified 2072 CTs in the database ClinicalTrials.gov: only 229 were fully published 276 . The other review included 744 CTs at different phases; 80% involved drug investigations 277 . Despite extensive efforts and enormous investment, only two classes of drugs, presenting mild symptomatic effects, have been introduced in clinical practice nearly two decades ago: cholinesterase blockers (rivastigmine, donepezil, galantamine) and one antagonist of glutamate NMDA receptors (i.e., memantine).…”

New approaches for the treatment of Alzheimer’s disease

“…85 These improvements in trial design and interpretation will clearly benefit from an increased publication of trial data which is currently just 27% of completed trials. 86 It is projected that by 2050 there will be 150 million people suffering with dementia globally with the majority having AD. 2 Effective treatments are urgently required to alleviate the symptoms and arrest progression of the disease.…”